Virus News and Research

Latest Virus News and Research

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of liver disease associated with AAT deficiency. These data were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, "The Liver Meeting") held November 9-13, 2012 in Boston.

15 Nov 2012

Potential diagnostic method to identify subset of patients with chronic fatigue syndrome

For the first time, researchers have landed on a potential diagnostic method to identify at least a subset of patients with chronic fatigue syndrome (CFS), a complex disorder with no known definitive cause or cure.

15 Nov 2012

Ebola, Marburg and Lassa viruses must be designated as emerging diagnoses

The Ebola, Marburg and Lassa viruses are commonly referred to as emerging diseases, but leading scientists say these life-threatening viruses have been around for centuries.

15 Nov 2012

NPR, GlobalPost examine polio in Nigeria

NPR's "Shots" blog reports on an update about the polio situation in Nigeria, published Thursday in the CDC's latest issue of Morbidity and Mortality Weekly Report (MMWR), writing, "Despite beefed-up efforts to vaccinate kids and a flood of new resources, ... there have been twice as many polio cases as last year, and a few communities, where kids chronically miss vaccines, are serving as 'sanctuaries' for the poliovirus, giving it a place to replicate and survive."

14 Nov 2012

Ligand Pharmaceuticals announces data from LG-7501 preclinical studies on HCV

Ligand Pharmaceuticals Incorporated announced that data from preclinical studies evaluating LG-7501 were featured in a poster presentation today at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases in Boston.

14 Nov 2012

Abbott releases details on phase 3 hepatitis C registrational program

Abbott today released details on its phase 3 hepatitis C registrational program following promising results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.

13 Nov 2012

Weight-based ribavirin undertreats African–American HCV patients

African–Americans with hepatitis C virus genotype 1 infections have lower ribavirin plasma exposures than Caucasian Americans when treated with weight-based ribavirin plus peginterferon.

12 Nov 2012

Close contact at school led to mumps outbreak in Orthodox Jewish communities

A 2009 outbreak of mumps in the USA that primarily affected Orthodox Jewish teenage boys may have been perpetuated by close schooling conditions, say the authors of a study published in The New England Journal of Medicine.

9 Nov 2012

New vaccines and drug treatments urgently needed for bacterial meningitis

New vaccines and drug treatments are urgently needed for bacterial meningitis, a devastating disease which kills or maims around a fifth of people who contract it, according to medical experts writing in a new Series on bacterial meningitis, published in The Lancet.

9 Nov 2012

RTS,S vaccine candidate can help protect African infants against malaria

International African Vaccinology Conference, Cape Town, South Africa-Results from a pivotal, large-scale Phase III trial, published online today in the New England Journal of Medicine, show that the RTS,S malaria vaccine candidate can help protect African infants against malaria.

9 Nov 2012

New intervention strategies needed to reach HIV-infected youth at birth

As youth infected at birth with HIV reach adolescence and young adulthood, a new study published in Clinical Infectious Diseases underscores the need to promote healthy behaviors as some of these young people become sexually active.

9 Nov 2012

Pevion launches Defensomes platform for broad spectrum immune enhancement

Pevion Biotech AG today announced the launch of a new program called Defensomes, a platform for broad spectrum immune enhancement via mechanisms of innate immunity. The proprietary technology is derived from a vaccine platform with a solid safety track record comprising more than 80 million doses applied to humans to date. Defensomes offer opportunities for a wide range of prophylactic and therapeutic indications, where boosting of the body's own natural defense is beneficial.

8 Nov 2012

BioCryst completes planned interim analysis of peramivir Phase 3 trial for serious influenza

BioCryst Pharmaceuticals, Inc. announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza. The difference between peramivir and control groups for the primary endpoint was small and the recalculated sample size was greater than the predefined futility boundary of 320 subjects. Based on this information, the independent data monitoring committee (DMC) recommended that the study be terminated for futility.

8 Nov 2012

HPV testing and cervical screening: an interview with Dr Rosa Legood

Human papillomavirus is a virus that is transmitted through sexual contact. In most cases the virus is transient and causes no harm, however in some cases it can go on to cause pre-cancer lesions and cervical cancer.

7 Nov 2012

Texas Biomed develops rapid, less expensive route to screen suitable tests for bioterror threats

Texas Biomedical Research Institute scientists in San Antonio have developed a faster, less expensive route to screen suitable tests for bioterror threats and accelerate the application of countermeasures.

7 Nov 2012

Alpha-herpesvirus axon-to-cell spread involves limited virion transmission

New research suggests that just one or two individual herpes virus particles attack a skin cell in the first stage of an outbreak, resulting in a bottleneck in which the infection may be vulnerable to medical treatment.

7 Nov 2012

WHO survey shows low knowledge level, acceptance of polio vaccine among Pashtun Pakistanis

"Polio will never be eradicated in Pakistan until a way is found to persuade poor Pashtuns to embrace the vaccine, according to a study released by the World Health Organization" in its November bulletin, the New York Times reports.

7 Nov 2012

SCYNEXIS announces results from SCY-635 Phase 2a study on HCV

SCYNEXIS, Inc. today announced that the results of a Phase 2a study of lead candidate SCY-635 for the treatment of the hepatitis C virus (HCV) will be the subject of an oral presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place from November 9-13 in Boston, Massachusetts.

7 Nov 2012

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.

6 Nov 2012

Gene silencing technology used to fight RSV and influenza

New hope has arrived for the fight against two deadly viral infections, RSV and influenza, as Griffith researchers prepare to develop a cutting-edge approach to treatment delivery.

6 Nov 2012